# US 2025/0091993 A1 · Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0091993 A1
- Document ID: US20250091993A1
- Status: Published application
- Kind: A1
- Application number: 18/832,754
- Filed: 2023-01-26
- Published: 2025-03-20
- Earliest claimed: 2022-01-27
- Assignees: Terran Biosciences Inc.
- Applicants: Terran Biosciences Inc.
- Inventors: Matthew DUNCTON; Samuel CLARK
- Web page: https://patentgrep.com/patent/US20250091993A1

## CPC

- C07D 209/16: Tryptamines
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C07C 53/06: Salts thereof
- C07C 53/10: Salts thereof
- C07C 55/07: Salts thereof
- C07C 55/10: Succinic acid
- C07C 55/12: Glutaric acid
- C07C 55/14: Adipic acid
- C07C 55/20: Sebacic acid
- C07C 57/12: Straight chain carboxylic acids containing eighteen carbon atoms
- C07C 59/105: having five or more carbon atoms, e.g. aldonic acids
- C07C 59/245: containing hydroxy or O-metal groups
- C07C 59/265: Citric acid
- C07C 59/285: Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed herein are salt and solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine. The solid form may be a salt and/or a crystalline form of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, such as a polymorph of N-eth-yl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The solid forms of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine are useful for treating neurological disease and/or a psychiatric disorder in a subject.

## Claims

### Claim 1

A compound, N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, wherein the compound is in the form of a salt.

### Claim 2

A solid form of (i) N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or (ii) a N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine salt.

### Claim 3 (depends on 2)

The solid form of claim 2, wherein the N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine salt is an acid addition salt.

### Claim 4 (depends on 2)

The solid form of claim 2, wherein the N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine salt is a crystalline salt formed from an acid selected from galactaric (mucic) acid, naphthalene-1,5-disulfonic acid, citric acid, sulfuric acid, d-glucuronic acid, ethane-1,2-disulfonic acid, lactobionic acid, p-toluenesulfonic acid, D-glucoheptonic acid, thiocyanic acid, (−)-L-pyroglutamic acid, methanesulfonic acid, L-malic acid, dodecylsulfuric acid, hippuric acid, naphthalene-2-sulfonic acid, D-gluconic acid, benzenesulfonic acid, D,L-lactic acid, oxalic acid, oleic acid, glycerophosphoric acid, succinic acid, ethanesulfonic acid 2-hydroxy, glutaric acid, L-aspartic acid, cinnamic acid, adipic acid, phosphoric acid, sebacic acid, ethanesulfonic acid, (+)-camphoric acid, glutamic acid, acetic acid, fumaric acid, or a combination thereof.

### Claim 5 (depends on 3)

The solid form of claim 3, wherein a stoichiometric ratio of acid to N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine is from 0.4 to 2.2.

### Claim 6 (depends on 3)

The solid form of claim 3, wherein a stoichiometric ratio of acid to N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine is from 0.5 to 2.

### Claim 7 (depends on 3)

The solid form of claim 3, wherein a stoichiometric ratio of acid to N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine is selected from 0.5, 1, or 2.

### Claim 8 (depends on 2)

The solid form of claim 2, wherein the solid form is a free base form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7, 8)

The solid form of any of claims 2 to 8, wherein the solid form is a hydrate.

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The solid form of any one of claims 2 to 9, wherein the solid form is a crystalline solid.

### Claim 11 (depends on 10)

The solid form of claim 10, wherein the crystalline solid is a substantially single polymorph.

### Claim 12 (depends on 11)

The solid form of claim 11, wherein the polymorph is selected to have one or more desired properties.

### Claim 13 (depends on 12)

The solid form of claim 12, wherein the one or more desired properties are selected from physical properties, chemical properties, pharmacokinetic properties, or a combination thereof.

### Claim 14 (depends on 12, 13)

The solid form of claim 12 or claim 13, wherein the one or more desired properties comprise melting point, glass transition temperature, flowability, thermal stability, shelf life, stability against polymorphic transition, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles, bioavailability, absorption, distribution, metabolism, excretion, toxicity including cytotoxicity, dissolution rate, half-life, or a combination thereof.

### Claim 15

The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, and 26.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 16

The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by signals at 25.1 °2θ, 16.5 °2θ, and 26.2 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 17

The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, and 17.0 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 18

The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, 17.0 °2θ, 11.0 °2θ, and 27.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 19

The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.1 °2θ, 16.5 °2θ, 26.2 °2θ, 15.1 °2θ, 17.0 °2θ, 11.0 °2θ, 27.8 °2θ, 27.2 °2θ, 31.0 °2θ, and 26.8 °2θ (±0.2 °2θ; ±0.1 °2θ; or ±0.0 °2θ; Cu Kα1 radiation).

### Claim 20

The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by a XRPD diffractogram substantially similar to that shown in FIG. 1.

### Claim 21

The compound of any of the preceding claims, wherein the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride is a crystalline polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine hydrochloride characterized by any combination of the XRPD peaks set forth in Table 1A.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A pharmaceutical composition, comprising the compound of claim 1 or the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine according to any one of claims 2 to 21, and a pharmaceutically acceptable excipient.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method, comprising administering to a subject an effective amount of the compound of claim 1, the solid form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine according to any one of claims 2 to 21, or the pharmaceutical composition according to claim 22.

### Claim 24 (depends on 23)

The method of claim 23, wherein the subject has a neurological disease, a psychiatric disorder, or both.

### Claim 25 (depends on 24)

The method of claim 24, wherein the neurological disorder is a neurodegenerative disorder.

### Claim 26 (depends on 24)

The method of claim 24, wherein the neurological disorder, psychiatric disorder, or both, comprises depression, addiction, anxiety, or a post-traumatic stress disorder.

### Claim 27 (depends on 24)

The method of claim 24, wherein the neurological disorder, psychiatric disorder, or both, comprises treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder.

### Claim 28 (depends on 24)

The method of claim 24, wherein the neurological disorder, psychiatric disorder, or both, comprises stroke, traumatic brain injury, or a combination thereof.

### Claim 29 (depends on 23, 24, 25, 26, 27, 28)

The method of any one of claims 23 to 28, wherein administering comprises oral, parenteral, or topical administration.

### Claim 30 (depends on 23, 24, 25, 26, 27, 28)

The method of any one of claims 23 to 28, wherein administering comprises oral administration.

### Claim 31 (depends on 23)

The method of claim 23, wherein administering comprises administering by injection, inhalation, intraocular, intravaginal, intrarectal or transdermal routes.

### Claim 32 (depends on 24)

The method of claim 24, further comprising administering to the subject an effective amount of an empathogenic agent.

### Claim 33 (depends on 32)

The method of claim 32, wherein the empathogenic agent is MDMA.

### Claim 34 (depends on 24)

The method of claim 24, further comprising administering a 5-HT2A antagonist to the subject.

### Claim 35 (depends on 34)

The method of claim 34, wherein the 5-HT2A antagonist is selected from MDL-11,939, eplivanserin (SR-46,349), ketanserin, ritanserin, altanserin, acepromazine, mianserin, mirtazapine, quetiapine, SB204741, SB206553, SB242084, LY272015, SB243213, blonanserin, SB200646, RS102221, nefazodone, MDL-100,907, pimavanserin, nelotanserin and lorcaserin.

### Claim 36

A compound, N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, in the form of a crystal, a salt, or both.

### Claim 37 (depends on 36)

The compound of claim 36, wherein the compound is in the form of a hydrochloride salt.

### Claim 38 (depends on 36, 37)

The compound of claim 36 or 37, wherein the compound is in a solid form.

### Claim 39 (depends on 36)

The compound of claim 36, wherein the compound is a crystalline form of the free base.

### Claim 40 (depends on 36)

The compound of claim 36, wherein the hydrochloride salt form is crystalline.

### Claim 41 (depends on 40)

The compound of claim 40, wherein the crystalline salt form is characterized by peaks in an XRPD diffractogram of about 11.0 °2θ+/−0.1 °2θ, 16.5 °2θ+/−0.1 °2θ, and 25.1 °2θ+/−0.1 °2θ.

### Claim 42 (depends on 40)

The compound of claim 40, wherein the crystalline salt form is characterized by peaks in the XRPD diffractogram of FIG. 1.
